Uro-BLUE

URO-BLUE- methenamine, sodium phosphate, monobasic, methylene blue and hyoscyamine sulfate tablet
Method Pharmaceuticals, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Uro-BLUE™ Tablets

Rx Only

Description

Each tablet contains:
Methenamine, USP 81.6 mg
Monobasic Sodium Phosphate, USP 40.8 mg
Methylene Blue 10.8 mg
Hyoscyamine Sulfate 0.12 mg

Inactive Ingredients include: Microcrystalline Cellulose, Mannitol, Croscarmellose Sodium, Magnesium Stearate, FD&C Blue #1

HYOSCYAMINE SULFATE is an alkaloid of belladonna. Exists as a white crystalline powder. Affected by light It is very soluble in water; freely soluble in alcohol; practically insoluble in ether.

METHENAMINE exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus. Freely soluble in water; soluble in alcohol and in chloroform.

METHYLENE BLUE exists as dark green crystals. It is soluble in water and in chloroform; sparingly soluble in alcohol.

MONOBASIC SODIUM PHOSPHATE exists as a white crystalline powder. Its solutions are acidic to litmus. It is freely soluble in water and practically insoluble in alcohol.

CLINICAL PHARMACOLOGY

HYOSCYAMINE is a parasympatholytic which relaxes smooth muscles and thus produces an antispasmodic effect. It is well absorbed from the gastrointestinal tract and is rapidly distributed throughout body tissues. Most is excreted in the urine within 12 hours, 13% to 50% being unchanged.

Its biotransformation is hepatic. Its protein binding is moderate.

METHENAMINE degrades in an acidic urine environment releasing formaldehyde which provides bactericidal or bacteriostatic action. It is well absorbed from the gastrointestinal tract. 70% to 90% reaches the urine unchanged at which point it is hydrolyzed if the urine is acidic. Within 24 hours it is almost completely (90%) excreted; of this amount at pH 5, approximately 20% is formaldehyde. Protein binding: some formaldehyde is bound to substances in the urine and surrounding tissues. Methenamine is freely distributed to body tissue and fluids but is not clinically significant as it does not hydrolyze at pH greater than 6.8.

METHYLENE BLUE possesses weak antiseptic properties. It is well absorbed in the gastrointestinal tract and is rapidly reduced to leukomethylene blue which is stabilized in some combination form in the urine. 75% is excreted unchanged.

MONOBASIC SODIUM PHOSPHATE helps to maintain an acid pH in the urine necessary for the degradation of methenamine.

Uro-BLUE Indications and Usage

Uro-BLUETM Tablets is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.

CONTRAINDICATIONS

Uro-BLUETM Tablets is contraindicated in patients with a hypersensitivity to any of the ingredients.

Risk-benefit should be considered when the following medical problems exist: Cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

WARNINGS

Do not exceed recommended dosage. If rapid pulse, dizziness, or blurring of vision occurs discontinue use immediately.

PRECAUTIONS

Cross sensitivity and/or related problems patients intolerant of belladonna alkaloids may be intolerant of this medication also.

Pregnancy/Reproduction

(Pregnancy Category C)

hyoscyamine and methenamine cross the placenta. Studies have not been done in animals or humans. It is not known whether Uro-BLUETM Tablets cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Uro-BLUETM Tablets should be given to a pregnant woman only if clearly needed.

Breast-feeding

problems in humans have not been documented; however, methenamine and traces of hyoscyamine are excreted in breast milk.

Prolonged use

there have been no studies to establish the safety of prolonged use in humans. No known long-term animal studies have been performed to evaluate carcinogenic potential.

Pediatric

infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids.

Geriatric

use with caution in elderly patients as they may respond to usual doses of hyoscyamine with excitement, agitation, drowsiness, or confusion.

Drug Interactions

because of this product’s effect on gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications during concurrent use such as: urinary alkalizers; thiazide diuretics (may cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde); antimuscarinics (concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications); antacids/antidiarrheals (may reduce absorption of hyoscyamine, concurrent use with antacids may cause urine to become alkaline reducing effectiveness of methenamine by inhibiting its conversion to formaldehyde) doses of these medications should be spaced 1 hour apart from doses of hyoscyamine; antimyasthenics (concurrent use with hyoscyamine may further reduce intestinal motility); ketoconazole (patients should be advised to take this combination at least 2 hours after ketoconazole); monoamine oxidase (MAO) Inhibitors (concurrent use may intensify antimuscarinic side effects, opioid (narcotic) analgesics may result in increased risk of severe constipation); sulfonamides (these drugs may precipitate with formaldehyde in the urine, increasing the danger of crystalluria).

Patients should be advised that the urine may become blue to blue green and the feces may be discolored as a result of the excretion of methylene blue.

Adverse Reactions to Uro-BLUE

Cardiovascular – rapid pulse, flushing

Central Nervous System – blurred vision, dizziness

Respiratory – shortness of breath or troubled breathing

Genitourinary – difficulty micturition, acute urinary retention

Gastrointestinal – dry mouth, nausea/vomiting

DRUG ABUSE AND DEPENDENCE

A dependence on the use of Uro-BLUETM Tablets has not been reported and due to the nature of its ingredients, abuse of Uro-BLUETM Tablets is not expected.

OVERDOSAGE

Emesis or gastric lavage. Slow intravenous administration of physostigmine in doses of 1 mg to 4 mg (0.5 mg to 1 mg in children), repeated as needed in one to two hours to reverse severe antimuscarinic symptoms. Administration of small doses of diazepam to control excitement and seizures. Artificial respiration with oxygen if needed for respiratory depression. Adequate hydration. Symptomatic treatment as necessary.

DOSAGE AND ADMINISTRATION

Adults

One tablet orally 4 times per day followed by liberal fluid intake.

Older Children

Dosage must be individualized by physician. Not recommended for use in children up to 6 years of age.

HOW SUPPLIED

Uro-BLUETM Tablets are light blue to blue, oval, biconvex tablets debossed with “M455″ with scoreline on one side and plain on the other side. Supplied in bottles of 100 tablets (NDC 58657-455-01).

CAUTION

RX ONLY

STORAGE

Store at 25° C (77° F); excursions permitted to 15° C to 30° C (59° F to 86° F) [See USP Controlled Room Temperature]. Keep container tightly closed.

Distributed By:
Method Pharmaceuticals, LLC
Arlington, TX 76006


Rev. Date: 04/2015

PRINCIPAL DISPLAY PANEL

NDC 58657-455-01
Uro-BLUE TM
Tablets
Rx ONLY
100 Tablets

PRINCIPAL DISPLAY PANEL
NDC 58657-455-01
Uro-BLUETM
Tablets
Rx ONLY	100 Tablets
(click image for full-size original)
URO-BLUE
methenamine, sodium phosphate, monobasic, methylene blue and hyoscyamine sulfate tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:58657-455
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
METHENAMINE (METHENAMINE) METHENAMINE 81.6 mg
SODIUM PHOSPHATE, MONOBASIC (SODIUM CATION) SODIUM PHOSPHATE, MONOBASIC 40.8 mg
METHYLENE BLUE (METHYLENE BLUE CATION) METHYLENE BLUE 10.8 mg
HYOSCYAMINE SULFATE (HYOSCYAMINE) HYOSCYAMINE SULFATE 0.12 mg
Inactive Ingredients
Ingredient Name Strength
CELLULOSE, MICROCRYSTALLINE
MANNITOL
CROSCARMELLOSE SODIUM
MAGNESIUM STEARATE
FD&C BLUE NO. 1
Product Characteristics
Color BLUE (light blue to blue) Score 2 pieces
Shape OVAL (biconvex) Size 13mm
Flavor Imprint Code M455
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:58657-455-01 100 TABLET in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
UNAPPROVED DRUG OTHER 12/01/2014
Labeler — Method Pharmaceuticals, LLC (060216698)

Revised: 04/2015 Method Pharmaceuticals, LLC

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.